TRK-IN-29

TRK-IN-29

• UNSPSC Description: TRK-IN-29 (Compound B31) is a second-generation TRK inhibitor (IC50: 9 nM, 0.6 nM, 18 nM, 5 nM, 6 nM for TRKAG595R, TRKAF589L, TRKAG667C, TRKA and TRKC respectively). TRK-IN-29 inhibits the phosphorylation of TRKA. TRK-IN-29 has good antiproliferative activities against NTRK fusion positive cells. TRK-IN-29 has exellent plasma stability and moderate pharmacokinetic properties[1].
• Target Antigen: Trk Receptor
• Type: Reference compound
• Related Pathways: Neuronal Signaling;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/trk-in-29.html
• Smiles: C[C@H](C1=CC(F)=CC=C1OCC(F)F)NC2=CC3=C(NN=C3N4N=CN=C4)C=C2
• Molecular Weight: 402.37
• References & Citations: [1]Qiaohua Qin, et al. Discovery of novel indazole derivatives as second-generation TRK inhibitors. European Journal of Medicinal Chemistry. Available online 1 July 2024, 116640, et al.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported